Posts tagged Sophiris
Maxim ups Sophiris price target to $6

Maxim Group raised it price target for Sophiris Bio (NASDAQ:SPHS) to $6 from $4, citing better data of the company’s topsalysin drug candidate. The stock closed at $5.04 on Tuesday.

Read More